Skip to main content

Peer Review reports

From: Phase II/III trial of hyperimmune anti-COVID-19 intravenous immunoglobulin (C-IVIG) therapy in severe COVID-19 patients: study protocol for a randomized controlled trial

Original Submission
23 Mar 2022 Submitted Original manuscript
16 Jun 2022 Reviewed Reviewer Report - Kirsty Loudon
18 Sep 2022 Reviewed Reviewer Report - Lucio Jesus García-Fraile García Fraile
18 Oct 2022 Author responded Author comments - Shaukat Ali
Resubmission - Version 2
18 Oct 2022 Submitted Manuscript version 2
21 Oct 2022 Editorially accepted
8 Nov 2022 Article published 10.1186/s13063-022-06860-2

You can find further information about peer review here.

Back to article page